INBX — Inhibrx Biosciences, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 2007919 ·
Last close
$74.18
Market Cap
$1.09B
52W High
$155.29
52W Low
$57.30
ADV30
275,858
Next earnings
2026-11-13
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 2,000,000 — -31,735,000 -38,733,000 220,291,000 199,469,000 306,167,000
Jun 2026 0 — -32,149,000 -36,650,000 154,222,000 133,344,000 207,199,000
Mar 2026 0 — -30,927,000 -33,441,000 183,967,000 161,657,000 205,002,000
Dec 2025 0 — -30,923,000 -32,834,000 146,478,000 124,220,000 138,485,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-131,889,000
Investing CF
$-7,000
Financing CF
$78,673,000
CapEx
$-31,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-8.88
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-316,278,000
Inventory
—
Receivables
$132,000
ST Investments
—
EBIT TTM
$-122,610,000
Pretax Income TTM
$-138,178,000
Interest Exp TTM
$15,568,000
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,000,000
EBITDA
$-123,601,000
Free Cash Flow
$-85,104,872
Enterprise Value
$1,386,707,968
Total Cash
$199,468,992
Total Debt
$276,700,992
Shares Out
14,717,660
Trailing EPS
$-8.88
Book Value
$-5.46
ROE
-1773.6%
ROA
-39.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 1,300,000 -135,025,000 -140,055,000 146,478,000 138,485,000 7,993,000 -129,794,000
Dec 2024 200,000 -331,448,000 1,687,572,000 180,767,000 47,183,000 133,584,000 -194,409,000
Dec 2023 1,800,000 -219,221,000 -241,361,000 307,893,000 264,390,000 43,503,000 -193,309,000
Dec 2022 1,301,000 -115,323,000 -115,325,000 16,645,000 23,945,000 -7,300,000 -90,811,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-138,181,000
OpCashFlow TTM
—
Assets (Latest)
$154,222,000
Forward EPS
$-8.76

Max Pain — expiry 2027-01-15

max pain strike: $65.00 · spot: $69.06 · call oi: 905 · put oi: 282
Expected Move to 2027-01-15: ±$30.55 (44.24%) — implied range $38.51 – $99.61 · ATM straddle on $70.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
VOR Vor Biopharma Inc. $1.12B $18.18 —
IMTX Immatics N.V. $957.50M $6.29 —
ODTX Odyssey Therapeutics, Inc. $931.07M $19.37 —
TSHA Taysha Gene Therapies, Inc. $1.30B $4.00 —
NVAX NOVAVAX INC $1.31B $7.96 —

News headlines (Yahoo Finance, 1h cache)

Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma
2026-11-17 21:53 · Yahoo
Inhibrx Reports Third Quarter 2026 Financial Results
2026-11-13 21:02 · Yahoo
Inhibrx Biosciences (INBX) Stock Looks Hard To Pin Down At This Price
2026-10-23 10:16 · Yahoo
Are Inhibrx Biosciences' (INBX) Global Data Reveals Reframing Its Late-Stage Pipeline Credibility?
2026-10-14 14:14 · Yahoo
Inhibrx Announces Participation in Upcoming Scientific Conferences
2026-10-13 20:00 · Yahoo
Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
2026-10-02 12:00 · Yahoo
Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall?
2026-09-24 17:07 · Yahoo
Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
2026-09-16 00:29 · Yahoo
Inhibrx Shares Rise After Positive Phase 2 Head and Neck Cancer Data
2026-09-08 12:51 · Yahoo
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
2026-09-08 11:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.